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Abstract Uterine sarcomas and mixed epithelial–mesen-
chymal uterine tumors are a heterogeneous group of rare
tumors for which there are very few diagnostic markers
available. As aberrant microRNA (miRNA) expression pat-
terns represent putative diagnostic cancer markers, we
aimed to identify miRNA expression profiles of the major
uterine sarcoma subtypes and mixed epithelial–mesenchy-
mal tumors of the uterus. Eighty-eight miRNAs were
assessed by quantitative RT-PCR in cancerous and non-
cancerous tissue samples collected from 29 patients with
endometrial sarcoma, leiomyosarcoma, and mixed epitheli-
al–mesenchymal tumors. Tumor and control samples signif-
icantly (P<0.05) differed in the expression of miR-23b,
miR-1, let-7f, and let-7c in endometrial sarcomas, and miR-
1, let-7c, miR-133b, let-7b, miR-143, let-7a, let-7d, let-7e,
let-7g, miR-222, let-7i, and miR-214 in mixed epithelial–
mesenchymal tumors. All the significantly changed
miRNAs were down-regulated in the malignant tissues as
compared to their normal counterparts. This may suggest
their tumor suppressor role in these malignancies. No statis-
tically significant changes in miRNA expression levels were
found between leiomyosarcoma tumors and controls. The
identified miRNAs warrant further studies as valuable can-
didate markers for the differential diagnosis of uterine sar-
comas from benign uterine lesions and between uterine
sarcoma subtypes.
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Introduction
Uterine sarcomas are a heterogeneous group of rare tumors
that constitute up to 8 % of cancers of the uterine corpus and
1 % of all tumors of the female genital tract [1, 2]. Uterine
sarcomas are classified as mesenchymal tumors (endometri-
al sarcomas and leiomyosarcomas) and mixed epithelial–
mesenchymal tumors (including adenosarcomas and carci-
nosarcomas) [3]. Carcinosarcomas were reclassified as a
dedifferentiated or metaplastic form of endometrial carcino-
ma but are still included in the 2003 World Health Organi-
zation (WHO) classification [3, 4]. Uterine sarcomas are
among the most lethal uterine malignancies with worse
prognosis than other gynecologic malignancies; 5-year sur-
vival rate is below 50 % for stage I and less than 30 % for
the remaining stages [2]. This group of tumors must be
considered in a differential diagnosis of patients with abnor-
mal uterine bleeding. Preoperative diagnosis of uterine sar-
comas, including imaging-based diagnosis, is extremely
difficult because there are no unambigous pathognomonic
features of this group of tumors. Since uterine sarcomas are
rarely diagnosed preoperatively, the initial treatment is often
based on an inappropriate diagnosis.
microRNAs (miRNAs, miRs) are approximately 22-
nucleotide long, non-coding RNAs that regulate the transla-
tion of the coding mRNAs. These molecules are generally
considered to be negative regulators of gene expression [5],
yet they may also function as inducers of translation [6].
miRNAs are involved in a variety of both normal and
pathological biological processes. They are key players in
the regulation of carcinogenesis where they may play a role
of either tumor inducers (so-called oncomirs) or supressors
[7]. Accumulating data on miRNAs’ expression in different
tumor types points to miRNAs as putative diagnostic, prog-
nostic, and predictive markers.
This study aimed at identification of miRNA expression
patterns in uterine sarcomas and mixed epithelial–mesen-
chymal uterine tumors.
Materials and methods
Ten patients treated for endometrial sarcoma, 8 for
leiomyosarcoma, and 11 treated for mixed epithelial–mesen-
chymal tumors at the Maria Sklodowska-Curie Memorial
Cancer Centre and Institute of Oncology in Warsaw, between
February 2009 and December 2010, were enrolled. The se-
lected patients’ characteristics are presented in Table 1. The
study was approved by the Independent Ethics Committee of
the Maria Sklodowska-Curie Memorial Cancer Centre and
Institute of Oncology in Warsaw and all patients gave their
informed consent. Tissue specimens were divided into two
parts: one part was examined histologically and the other was
frozen in liquid nitrogen and stored at −70 °C until RNA
isolation. In addition to 29 tumor tissue samples, 12 samples
of normal uterine tissue were also collected from patients
enrolled in the study.
Human uterine sarcoma cell lines MES-SA (CRL-1976,
derived from a poorly differentiated uterine sarcoma) and
SK-UT-1 (derived from mixed mesodermal tumor) pur-
chased from the American Type Tissue Collection, were
cultured in the McCoy’s 5A and Dulbecco’s modified Ea-
gle’s medium, respectively, supplemented with 10 % of FCS
(Gibco) and gentamycin (Sigma). Cells were seeded at 50×
103, in 75-cm2 bottles and passaged every 4–5 days by
trypsinisation. 5×106 cells were collected, washed three
times in PBS at 4 °C, snap-frozen and stored at –70 °C until
RNA isolation.
Total RNA was isolated from approximately 50 mg of
pulverized (with the Microdismembrator II, B Braun Biotech
International) tissues as well as from harvested MES-SA and
SK-UT-1 cell lines using miRNeasy Mini Kit with on-column
DNase digestion (Qiagen), according to the manufacturer’s
protocol. RNA quantity was assessed using the NanoDrop
2000 Spectrophotometer (ThermoScientific), while its quality
was visually assessed following gel electrophoresis using
FlashGel System (Lonza). RNAwas extracted from 41 tissue
samples (29 tumors and 12 control samples, i.e., fragments of
normal uterine tissues). Reverse transcription was performed
on 1 μg total RNA with the RT2 miRNA First Strand Kit
(Qiagen) and used for Human Cancer microRNA PCRArrays
(MAH-102 from SABiosciences, miRNA list available at
http://www.sabiosciences.com/mirna_pcr_product/HTML/
MAH-102A.html).
Quantitative real-time PCR (qPCR) analysis was performed
with the RT2 Real-Time PCR Master Mix (SABiosciences) in
the 7500 Fast Real-Time PCR System (Applied Biosystems)
following the manufacturer’s protocol (SABiosciences). The
collected data were analyzed using threshold-cycle (Ct) values
for the miRNAs with the SDS 2.1 software (Applied
Biosystems). The normalized miR expression values in uterine
sarcomas and mixed epithelial–mesenchymal uterine tumors
as well in the cell lines were determined with DataAssist
software (Applied Biosystems).
The Wilcoxon signed-rank test was used to test signifi-
cance of difference in miRs’ expression between the tumor
tissues and control samples. The statistical analysis was
carried out using the R software (version 2.14.1, http://
www.R-project.org). P values were corrected for multiple
hypotheses using Benjamini–Hochberg algorithm. The dif-
ferences were considered statistically significant at P<0.05.
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Expression levels for the selected miRs were graphed using
R software.
Results
Four potential reference genes for RT-qPCR application,
namely SNORD44, SNORD47, SNORD48, and RNU6-2,
were evaluated for normalization in 41 tissue samples (29
tumors and 12 fragments of normal uterine tissues) as well
as in the two human sarcoma cell lines: MES-SA and SK-
UT-1. Based on the expression stability values obtained in
the data analysis using the geNorm™ algorithm (integrated
into DataAssist software), SNORD47 and RNU6-2 were
chosen as reference genes.
miRNAs isolated from 41 fresh-frozen specimens obtained
from patients with uterine sarcomas and mixed epithelial–
mesenchymal uterine tumors were tested for the expression
of 88 types of miRNA known to be involved in carcinogen-
esis. Expression levels were analyzed using DataAssist soft-
ware and values were normalized to SNORD47 and RNU6-2.
Fold changes in the median expression values of miRs
that were significantly differentially expressed between tu-
mor (n=29) and control (n=12) samples are presented in
Table 2. The fold changes in the miRs’ expression values in
the MES-SA and SKUT-1 cell lines related to the control
Table 1 Individual patient data
Patient Age (years) Tumor type Tumor histology/histological grade Samples
analyzed
Mesenchymal tumors Endometrial sarcomas 6 76.7 Recurrent Endometrial stromal sarcoma, low grade T
13 60.1 Recurrent Undifferentiated endometrial sarcoma T
16 43.3 Primary Undifferentiated endometrial sarcoma T
17 74.8 Primary Undifferentiated endometrial sarcoma T, C
31 51.0 Primary Endometrial stromal sarcoma, low grade T, C
36 64.6 Primary Undifferentiated endometrial sarcoma T, C
38 44.8 Primary Endometrial stromal sarcoma, low grade T, C
52 78.1 Primary Undifferentiated endometrial sarcoma T
62 53.4 Primary Undifferentiated endometrial sarcoma T, C
64 68.9 Primary Undifferentiated endometrial sarcoma T
Smooth muscle tumors 2 52.6 Recurrent Leiomyosarcoma/G3 T, C
12 56.3 Primary Leiomyosarcoma/G3 T, C
23 63.2 Recurrent Leiomyosarcoma/G2 T
26 45.8 Recurrent Leiomyosarcoma/G3 T
28 51.5 Recurrent Leiomyosarcoma/G2 T
35 57.5 Recurrent Leiomyosarcoma/G2 T
63 40.5 Recurrent Leiomyosarcoma/G3 T
90 59.1 Recurrent Leiomyosarcoma/G2 T
Mixed epithelial and
mesenchymal tumors
3 75.5 Recurrent Carcinosarcoma heterologousa T
11 61.4 Primary Carcinosarcoma homologousb T, C
14 23.2 Primary Adenosarcoma homologous T, C
18 66.4 Primary Carcinosarcoma heterologous T
24 66.6 Primary Carcinosarcoma heterologous T, C
25 61.0 Recurrent Carcinosarcoma homologous T
30 64.3 Primary Carcinosarcoma heterologous T, C
66 55.1 Primary Carcinosarcoma homologous T, C
67 59.7 Primary Adenosarcoma homologous T
71 55.5 Recurrent Adenosarcoma homologous T
86 53.8 Recurrent Adenosarcoma homologous T
Abbreviations: T tumor sample, C control, i.e., a sample of normal uterine tissue obtained from the same patient
a Heterologous tumor—representing malignant counterparts that normally do not occur in the uterus
b Homologous tumor—representing malignant counterparts of tissues indigenous to the uterus
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uterine tissue samples, compared to the results obtained in
clinical samples, are provided in Electronic supplementary
material (ESM) Supplementary Fig. 1.
Subsequently, the expression data were analyzed within the
three groups of uterine tumors—endometrial sarcomas (n=10),
leiomyosarcomas (n=8), and mixed epithelial–mesenchymal
tumors (n=11)—compared to all the control (n=12) samples.
Four miR genes, namely miR-23b, miR-1, let-7f, and let-7c,
were found to be down-regulated in endometrial sarcomas
when compared to the control samples (see Fig. 1). The ex-
pression levels of 12 miRs, miR-1, let-7c, miR-133b, let-7b,
miR-143, let-7a, let-7d, let-7e, let-7g,miR-222, let-7i, andmiR-
214, which were down-regulated in mixed epithelial–mesen-
chymal tumors are presented in Fig. 2. The expression of the
above-mentioned miRs’ presented in Figs. 1 and 2 significantly
differed (P<0.05) between the tumor and control samples. No
statistically significant changes in miRNA expression levels
were found between leiomyosarcoma tumors and controls.
The fold change values in the median expression of all
the analyzed miRs between tumor and control samples,
stratified by the disease type, are presented in ESM Supple-
mentary Table 1.
Discussion
Uterine sarcomas present a significant therapeutic problem.
Clinical data demonstrate the aggressive behavior of these
tumors, with a high recurrence rate, and despite develop-
ment of new adjuvant treatments patient outcomes have not
improved. The benefits of chemotherapy are limited, and
radiotherapy can result in a lower rate of local recurrence but
Table 2 Fold changes
(FC) in the median ex-
pression values of the
significantly (P<0.05)
differentially expressed
miRs in all the analyzed
tumors (n=29) com-
pared to control (n=12)




signed rank test adjusted
for multiple hypotheses
testing

















Fig. 1 Differential expression of miR-23b, miR-1, let-7f, and let-7c in the normal uterine fragments (controls, C) and in endometrial sarcoma
tumors (T). Lines indicate median values
2156 Tumor Biol. (2013) 34:2153–2160
still has no effect on patients’ overall survival [8]. Imple-
mentation of targeted therapy and individualized treatment
of uterine sarcoma patients appears necessary [4]. Different
course of this disease is associated not only with the
Fig. 2 Differential expression of miR-1, let-7c, miR-133b, let-7b, miR-
143, let-7a, let-7d, let-7e, let-7g, miR-222, let-7i, and miR-214 in the
normal uterine fragments (controls, C) and in the mixed epithelial–
mesenchymal uterine tumors (T). Lines indicate median values
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histopathological variety of the tumors, as even patients
with the same diagnosis may present different disease
course. However, while individualized treatment should be
based on preoperative diagnosis, the differential diagnosis
of uterine tumors frequently causes problems [9].
Our goal was to identify alterations in miRNA expression
in pure mesenchymal tumors and mixed epithelial–mesen-
chymal tumors of the uterus. The vast majority of 88 miR
molecules analyzed here was down-regulated in the ana-
lyzed tumors when compared to normal uterine fragments.
Pan et al. [10] observed a significantly lower number of
miRNAs expressed in leiomyomas compared with normal
myometrium, and a further reduction of miRNA expression
in T-LSMC, a transformed culture of leiomyoma and
SKLM-1, a leiomyosarcoma cell line, provided grounds to
the authors’ hypothesis on the biological significance of
these miRNAs and their target genes in the pathogenesis
of leiomyosarcoma. Our observations were consistent with
this hypothesis and extended it to uterine leiomyosarcomas
as well as to endometrial sarcomas and mixed epithelial–
mesenchymal tumors.
To our knowledge, miRNA signatures of uterine pure
mesenchymal and mixed epithelial–mesenchymal tumors
of different subtypes have not been previously studied. In
our study, four miRs, i.e., miR-23b, miR-1, let-7f, and let-7c,
were found to be down-regulated in endometrial sarcomas
vs. control samples.
In the only other study to have examined miR expression
in mixed uterine tumors, Ratner et al. [11] found miRNA
signatures that discriminated carcinosarcomas from uterine
carcinomas. In carcinosarcomas, they revealed up-regulated
miR-19a and miR-19b—compared to endometrioid tumors,
miR-182—compared to papillary serous carcinomas, miR-
301, miR-20b, and miR-487b—jointly compared to
endometrioid and papillary serous tumors. The down-
regulated miRs in carcinosarcomas included miR-133a—as
compared to endometrioid tumors, miR-22—as compared to
papillary serous carcinomas, and miR-518b—as compared
to endometrioid and papillary serous tumors, jointly. In
accordance, we found mixed tumors to over-express miR-
19a, miR-301a, and miR-20b; however, this has not reached
statistical significance. The remaining miR molecules (miR-
19b, miR-182, miR-487b, miR-133a, miR-22, and miR-
518b) warrant further investigation. As we showed here,
mixed epithelial–mesenchymal tumors compared to the nor-
mal uterine fragments, expressed decreased levels of 12
miRs (miR-1, let-7c, miR-133b, let-7b, miR-143, let-7a,
let-7d, let-7e, let-7g, miR-222, let-7i, and miR-214).
Pan et al. [10] documented miR-20a, miR-21, and miR-
206 to be up-regulated and miR-142-5p to be down-
regulated in leiomyomas obtained from Caucasians as nor-
malized to normal myometrium. The results obtained by
Wang et al. [12] indicate that uterine leiomyomas, when
compared to the matched myometrium, have a homogenous
and specific miRNA signature, involving significantly over-
expressed let-7 family, miR-21, miR-23b, and miR-27a as
well as down-regulated miR-29b, miR-32, miR-144, and
miR-212. Table 3 summarizes a comparison between our
results and those of Pan et al. [10] and Wang et al. [12] on
leiomyomas, and reveals that a decrease in miR-29b and
miR-212 expression is commonly shared by leiomyomas,
uterine sarcomas, and mixed epithelial–mesenchymal tu-
mors. Studies in a mouse model of rhabdomyosarcoma have
shown that reconstitution of miR-29b/c [13] and miR-206
[14] inhibits tumor growth and stimulates muscle differen-
tiation, suggesting their role of a tumor suppressor. Corre-
spondingly, miR-29b was down-regulated in all tumors
examined in our study. However, an unexpected trend
(though insignificant) towards miR-206 up-regulation was
observed in endometrial sarcomas and mixed epithelial–
mesenchymal tumors. Similarly Pan et al. [15] demonstrated
miR-206 to be up-regulated in ectopic endometrium
Table 3 Comparison of our re-
sults with those obtained by Pan
et al. [10] and Wang et al. [12]
for leiomyomas
“↑” – increased, “↓” – decreased,
and “–” unchanged expression
levels in tumors vs control
samples





Leiomyosarcomas Mixed epithelial–mesenchymal tumors
miR-20a ↑ [10] ↑ ↓ ↑
miR-21a ↑ [10, 12] ↓ ↓ ↓
miR-206 ↑ [10] ↑ ↓ ↑
miR-142-5p ↓ [10] ↑ ↓ ↑
let-7 familya ↑ [12] ↓ ↓ ↓
miR-23ba ↑ [12] ↓ ↓ ↓
miR-27aa ↑ [12] ↓ ↓ ↓
miR-29b ↓ [12] ↓ ↓ ↓
miR-32a ↓ [12] ↑ ↑ ↑
miR-144a ↓ [12] – – –
miR-212 ↓ [12] ↓ ↓ ↓
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compared to the paired eutopic endometrium of women with
endometriosis. In a recent study, Jin et al. [16] demonstrated
that angiotensin II (Ang II) increased the expression of miR-
132 and miR-212 cluster (miR-132/212) in rat vascular
smooth muscle cells (RVSMC) in vitro, and in the aortas
of Ang II-infused mice in vivo. These authors observed a
positive feedback loop mechanism between cyclic AMP-
response element binding protein activation and miR-132
expression and revealed that a subset of genes down-
regulated by Ang II was a predicted target of miR-132. A
key role of miR-132/212 in Ang II-induced monocyte
chemoattractant protein-1 (MCP-1) gene expression in
RVSMC was discovered. In RVSMC, Jin et al. [16] proved
that phosphatase and tensin homolog (PTEN) is a target of
miR-132, and that the induction of MCP-1 occurs via PTEN
repression. Mutational inactivation of PTEN is not a com-
mon event in uterine sarcomas [17, 18], though in carcino-
sarcomas it may play a tumorogenic role [19]. Our data do
not support the repression of PTEN in uterine sarcomas and
mixed epithelial–mesenchymal tumors via miR-132/212, as
both members of this cluster were down-regulated in all the
tumors analyzed in our study.
Importantly, the distinct patterns of expression of miR-21,
let-7 family, miR-23b, and miR-27a between our samples
and leiomyomas examined by Pan et al. [10] and Wang et al.
[12] make these molecules putative markers distinguishing
uterine sarcomas and mixed epithelial–mesenchymal tumors
from leiomyomas. All these miRs were up-regulated in
leiomyomas and commonly down-regulated in the tumors
analyzed in our study. miR-21 is a proapoptotic oncomir
[20], regulating multiple programs that enhance cell prolif-
eration, apoptosis, and tumor invasiveness by targeting, e.g.,
PTEN, PDCD4, and RECK [21]. Its increased expression
has been observed in many tumors, including endometrial
cancer [22] and cervical cancer [23]. Our findings on miR-
21 are similar to those in eutopic endometrium of women
with endometriosis by Pan et al. [15] who demonstrated a
slight down-regulation of miR-21 in these tissues compared
to normal endometrium. miR-23b also functions as an
oncomir, by targeting proline oxidase (POX), which sup-
presses proliferation and induces apoptosis through genera-
tion of reactive oxygen species [24] and by inhibiting
invasion via suppressing several prometastatic genes [25].
An oncomir activity of miR-27a has also been observed. It
down-regulates prohibitin (PHB, anti-proliferative protein),
as documented in gastric adenocarcinoma cells [26], and
targets Sprouty2 (Spry2, tumor supressor, an antagonist of
the Ras/MAPK signaling pathway) in pancreatic adenocar-
cinoma cells [27]. In view of the above, our results on the
three oncomirs, miR-21, miR-23b, and miR-27a, to be
under-expressed in tumor samples may suggest that their
oncogenic role is relative. Yet our findings on a common
decrease in the expression of the let-7 family members
(let-7a, let-7b, let-7c, let-7d, let-7e, let-7f, let-7g and let-7i)
in tumor samples support the notion of let-7 family members
as tumor suppressors influencing survival [28 and references
therein]. Most or all let-7 family members are down-
regulated in many cancer types, including sarcomas [29].
Additional putative markers distinguishing uterine sarco-
mas and mixed epithelial–mesenchymal tumors from
leiomyomas are miR-32 and miR-144 molecules. According
to Pan et al. [10] both miRs are down-regulated in
leiomyomas. MiR-32 was commonly up-regulated in all the
tumors analyzed in our study while the expression ofmiR-144
remained unchanged when compared to the control samples.
miR-32 may have an anti-apoptotic activity, as in human
leukemia 60 (HL60) cells it was shown to reduce the expres-
sion of BCL2L11 encoding the proapoptotic protein Bim [30].
miR-144 (functioning in a cluster with miR-451) promotes
erythropoiesis [31], down-regulates insulin receptor substrate
1 (IRS1) [32] and represses NRF2 [33], a key regulator of
oxidative stress response in erythrocytes. miR-144 confers
protection against simulated ischemia/reperfusion-induced
cardiomyocyte death via targeting CUG triplet repeat-
binding protein 2 (CUGBP2)–COX-2 pathway [34].
This preliminary study also provides hints for the future
investigations on the altered miRs that have not reached the
statistical significance in our small series of samples. The
fold change values of the average expression of all the
analyzed miRs between tumor and control samples are
provided in ESM Supplementary Table 1. In addition, our
results on miR expression in the uterine sarcoma cell lines,
SK-UT-1 and ME-SA, presented in ESM Supplementary
Fig. 1, demonstrate a marked discrepancy between the pro-
files of cell lines and the matched clinical material and prove
that cell lines are inadequate controls for miRNA studies in
uterine sarcomas.
To conclude, we identified miRNAs, which are
deregulated in uterine sarcomas and mixed epithelial–
mesenchymal uterine tumors. While we recognize the
low number of tissues profiled by a histopathological
subtype as a limitation of our study, this is the first
report on differential miRNA signatures across the sub-
types of uterine sarcomas. By identifying significant dif-
ferences in miRs’ expression levels in tumors compared
to normal uterine tissues (Figs. 1 and 2)—though, per-
haps due to the small series of samples, no specific
miRNA subset classifying these subtypes was distin-
guished—our findings provide insights into the biology
of these tumors. Some of these molecules, when further
validated, may prove to have a value of biomarkers for
uterine lesions. Profiling miR expression in uterine sar-
comas and mixed uterine tumors and other uterine enti-
ties may provide a valuable tool for the differential
diagnosis between uterine tumor subtypes and between
malignant and benign uterine pathologies.
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